Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008; 336:(7653)1121-1123

Bradford L, Ringshaw J, Wedderburn CJ Brain structure of South African HEU children exposed to dolutegravir versus efavirenz. Top Antivir Med.. 2024; 32:(1)

Carstens RP, Kapoor Y, Vargo R Single dose administration of MK-8527, a novel nRTTI, in adults with HIV-1. Top Antivir Med.. 2024; 32:(1)

Colson A, Crofoot G, Ruane PJ Efficacy and safety of weekly islatravir plus lenacapavir in PWH at 24 weeks: A phase II study. Top Antivir Med.. 2024; 32:(1)

Erlandson KM, Umbleja T, Ribaudo HJ Pitavastatin has no effect on long-term, objective physical function in REPRIEVE. Top Antivir Med.. 2024; 32:(1)

Feinstein MJ, Hsue PY, Benjamin LA Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation.. 2019; 140:(2)e98-e124

Fichtenbaum CJ, Berhe M, Bordon J Antiviral activity, safety, and pharmacokinetics of GS-1720: a novel weekly oral InSTI. Top Antivir Med.. 2024; 32:(1)

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet.. 2024; 403:(10440)2100-2132

Griffiths G, Fitzgerald R, Jaki T AGILE-ACCORD: A randomized, multicentre, seamless, adaptive phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial. Trials.. 2020; 21:(1)

Grinspoon SK, Fitch KV, Zanni MV Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023; 389:(8)687-699

Hickey M, Owaraganise A, Ogachi S Community health worker-facilitated telehealth for severe hypertension care in Kenya and Uganda. Top Antivir Med.. 2024a; 32:(1)

Hickey M, Grochowski J, Mayorga-Munoz F 24-week viral suppression in patients starting long-acting CAB/RPV without HIV viral suppression. Top Antivir Med.. 2024b; 32:(1)

Kityo CM, Mambule IK, Sokhela S Randomized trial of cabotegravir and rilpivirine long-acting in Africa (CARES): Week 48 results. Top Antivir Med. 2024; 32:(1)

Kolossváry M, Schnittman SR, Zanni M Pitavastatin reduces non-calcified plaque via pro-collagen PCOLCE independently of LDL in REPRIEVE. Top Antivir Med.. 2024; 32:(1)

Longenecker CT, Jones KA, Hileman CO A nurse-led strategy improves blood pressure and cholesterol in people with HIV: the EXTRA-CVD trial. Top Antivir Med. 2024a; 32:(1)

Longenecker CT, Jones KA, Hileman CO Nurse-led strategy to improve blood pressure and cholesterol level among people with HIV: a randomized clinical trial. JAMA Netw Open. 2024b; 7:(3)

Malaba TR, Nakatudde I, Kintu K 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. Lancet HIV.. 2022; 9:(8)e534-e543

Malaba TR, Orrell C, Else L ART adherence and elevated viral load in pregnant & postpartum women initiating DTG versus EFV. Top Antivir Med.. 2024a; 32:(1)

Malaba TR, Nassiwa S, He N DTG versus EFV initiation in pregnancy is not associated with postpartum blood pressure. Top Antivir Med.. 2024b; 32:(1)

Rana AI, Bao Y, Zheng L Long-acting injectable CAB/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359 [LATITUDE]. Top Antivir Med.. 2024; 32:(1)

Sax PE, Thompson MA, Saag MS IAS-USA Treatment Guidelines Panel. Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA Guidelines Panel. JAMA.. 2024; 331:(12)1060-1061

van der Wekken-Pas L, Nassiwa S, Malaba T Dolutegravir versus efavirenz: Depression, anxiety, and sleep disorders in pregnancy and postpartum. Top Antivir Med.. 2024a; 32:(1)

van der Wekken-Pas L, Nassiwa S, Malaba T Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV. AIDS.. 2024b; 38:(7)975-981

Waters L, Winston A, Reeves I BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022. HIV Med. 2022; 23:(Suppl 5)3-115

Yan LD, Rouzier V, Sufra R Treatment of prehypertension in people living with HIV: a randomized controlled trial. Top Antivir Med.. 2024; 32:(1)

Cardiovascular disease, medication regimens and HIV in pregnancy: new research relevant to nurses

06 June 2024
Volume 33 · Issue 11


People living with HIV have an increased risk of cardiovascular disease (CVD) compared with the general population due to a combination of traditional risk factors.

The 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) was held in Denver, Colorado over 3–6 March 2024 ( The CROI conference is a forum for both basic scientists and clinical investigators to present their research findings in HIV, hepatitis, SARS-CoV-2, mpox and other viral infections and their related conditions. The conference had a mixture of plenary sessions, oral abstract presentations, themed discussions, interactive symposia, and poster presentations. Out of a total of 1902 submitted abstracts, 1067 were selected for presentation.

The author attended CROI as part of a team presenting research results from DolPHIN-2, a trial evaluating the safety and efficacy of dolutegravir when initiated in late pregnancy (Malaba et al, 2022), and results from the AGILE clinical trial platform, an early phase clinical trial platform for the treatment of COVID-19 (Griffiths et al, 2020). This report summarises findings from the conference sessions attended.

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content